ENLV Enlivex Limited

NASDAQ
$1.47

Enlivex Limited (ENLV) is expected to report earnings on May 29, 2026, before the market open. The consensus earnings estimate is a loss of $0.31 per share.

Earnings Date
2nd Quarter, Jun 2026
May 29
Friday · Before Open
Earnings Whisper
-
vs ($0.31)
Volatility
Enter your expectations below to reveal the current volatility.
Trend Analysis
Expectation
Earnings
Price action
Signals
Score
Sentiment
Grade
Life Cycle
Call Analysis
Earnings-AVWAP -

Sign in or subscribe to unlock sentiment, short interest, and technical indicators.

About Enlivex Limited

Enlivex is a clinical stage immunotherapy company, developing an allogeneic drug pipeline for immune system rebalancing. Immune system rebalancing is critical for the treatment of life-threatening immune and inflammatory conditions which involve hyper-expression of cytokines (Cytokine Release Syndrome) and for which there are no approved treatments (unmet medical needs), as well as solid tumors immune-checkpoint rebalancing.

Sector

Healthcare

Industry

Drug Manufacturers/Other